Skip to main content
SpringerLink
Log in

Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Cytochrome P450 2C9 (CYP2C9) is involved in metabolism of many important drugs and its genotype variations is thought to affect drug efficacy and the treatment process. The aim of this study was to assess the distribution of CYP2C9 allele and genotypic variants in Sistani ethnic group, living in Gorgan, South East of Caspian Sea and North East of Iran. This study included 140 Sistani, referred to the health center of Gorgan. CYP2C9 genotyping was carried out by polymerase chain reaction–restriction fragment length polymorphism technique. The allele frequency of CYP2C9*1, CYP2C9*2 and CYP2C9*3 was 76.1, 16.1 and 7.8%, respectively. The frequency of CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes was 53.9, 22.1, 11.4, 2.9, 4.3% and nil, respectively. In this study the genotypic variations of the CYP2C9 allele among the Sistani ethnic group was investigated and great differences were observed in comparison to other populations. Our findings suggest that different genotypes of CYP2C9 may influence the pharmacokinetics of some drugs. More studies on the pharmacokinetic effects of CYP2C9 genotypes may help physicians choose optimal dosage of some drugs for treatment and prevention of their side effects. Since different ethnic groups from all over the world use medications, it suggests to investigate the pharmacokinetic effects of CYP2C9 genotypes in different populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics. 2002;12:251–63.

    Article  CAS  PubMed  Google Scholar 

  2. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994;4:285–99.

    Article  CAS  PubMed  Google Scholar 

  3. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52:349–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Garcıá-Martıń E, Martıńez C, Ladero JM, Aguńdez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006;10(1):29–40.

    Article  PubMed  Google Scholar 

  5. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005;7:97–104.

    Article  CAS  PubMed  Google Scholar 

  6. Miners J, Birkett D. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998;45:525–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zanger U, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392:1093–108.

    Article  CAS  PubMed  Google Scholar 

  8. Burian M, Grösch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol. 2002;54:518–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ, et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther. 2005;77:353–64.

    Article  CAS  PubMed  Google Scholar 

  10. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010;20:277–81.

    PubMed  PubMed Central  Google Scholar 

  11. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27:9–54.

    Article  CAS  PubMed  Google Scholar 

  12. Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. World allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet. 2010;55:582–9.

    Article  CAS  PubMed  Google Scholar 

  13. Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther. 2006;80:169–78.

    Article  CAS  PubMed  Google Scholar 

  14. Ghiyas Tabari M, Naseri F, Agh Ataby M, Marjani A. Genetic polymorphism of cytochrome p450 (2C9) enzyme in Iranian Baluch Ethnic Group. Open Biochem J. 2015;9:37–41.

    Article  PubMed  Google Scholar 

  15. Agh Ataby O, Ghiyas Tabari R, Mansourian AR, Mansour Samai N, Marjani A. Genetic polymorphism of cytochrome P450 2C9 (CYP2C9) in two ethnic groups in Iran. Am J Biomed Sci. 2013;5(3):177–87.

    Article  Google Scholar 

  16. Chang M, Dahl M-L, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics. 1995;5:358–63.

    Article  CAS  PubMed  Google Scholar 

  17. Brosen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics. 1995;5:312–7.

    Article  CAS  PubMed  Google Scholar 

  18. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717–9.

    Article  CAS  PubMed  Google Scholar 

  19. Azarpira N, Namazi S, Hendijani F, Banan M, Darai M. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran. Pharmacol Rep. 2010;62(4):740–6.

    Article  CAS  PubMed  Google Scholar 

  20. Mirghani RA, Chowdhary G, Elghazali G. Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population. Basic Clin Pharmacol Toxicol. 2011;109(2):111–4.

    Article  CAS  PubMed  Google Scholar 

  21. Yang Z, Cui H, Hasi T, Jia S, Gong M, Su X. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. Genet Mol Res. 2010;9(3):1844–51.

    Article  CAS  PubMed  Google Scholar 

  22. Ota T, Kamada Y, Hayashida M, Iwao-Koizumi K, Murata S, Kinoshita K. Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population. Int J Med Sci. 2015;12(1):78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Tavridou A, Manolopoulos VG. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007;21(4):419–26.

    Article  CAS  PubMed  Google Scholar 

  24. Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res. 2004;50(2):195–200.

    Article  CAS  PubMed  Google Scholar 

  25. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003;59(4):303–12.

    Article  CAS  PubMed  Google Scholar 

  26. Sipeky C, Lakner L, Szabo M, Takacs I, Tamasi V, Polgar N, et al. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies. Blood Cells Mol Dis. 2009;43(3):239–42.

    Article  CAS  PubMed  Google Scholar 

  27. Jakjovski K, Labachevski N, Petlichkovski A, Senev A, Trojacanec J, Atanasovska E, et al. Distribution of CYP2C9 and VKORC1 gene polymorphisms in healthy Macedonian male population. Maced J Med Sci. 2013;6(4):339–43.

    Article  CAS  Google Scholar 

  28. Buzoianu AD, Trifa AP, Mureşanu DF, Crişan S. Analysis of CYP2C9*2, CYP2C9*3 and VKORC1-1639 G>A polymorphisms in a population from South-Eastern Europe. J Cell Mol Med. 2012;16(12):2919–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Castelán-Martínez OD, Hoyo-Vadillo C, Sandoval-García E, Sandoval-Ramírez L, González-Ibarra M, Solano-Solano G, et al. Allele frequency distribution of CYP2C9*2 and CYP2C9*3 polymorphisms in six Mexican populations. Gene. 2013;523(2):167–72.

    Article  PubMed  Google Scholar 

  30. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002;72:326–32.

    Article  CAS  PubMed  Google Scholar 

  31. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002;71:286–96.

    Article  CAS  PubMed  Google Scholar 

  32. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman- Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 1999;254:628–31.

    Article  CAS  PubMed  Google Scholar 

  33. Herman D, Dolzan V, Breskvar K. Genetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian population. ZDRAV VESTN. 2003;72:347–51.

    Google Scholar 

  34. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329–33.

    Article  CAS  PubMed  Google Scholar 

  35. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol. 2002;53:596–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Isaza C, Henao J, Martínez JH, Arias JC, Beltrán L. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clin Pharmacol. 2007;7:6.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol. 2007;34:102–5.

    Article  CAS  PubMed  Google Scholar 

  38. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999;9(1):71–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the Research Deputy of Golestan University of Medical Sciences for financial support. This research project was derived from research proposal in Clinical Biochemistry. The corresponding author wishes to thank Mr. Aman Mohammad Gharanjik for his sincere help.

Funding

This work has been supported by the Research Deputy of Golestan University of Medical Science.

Author information

Authors and Affiliations

  1. Metabolic Disorders Research Center, Department of Biochemistry and Biophysics, Gorgan Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Golestan Province, Iran

    Abdoljalal Marjani

  2. Student Research Committee, Gorgan Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Golestan Province, Iran

    Aman Mohammad Gharanjik

Authors
  1. Abdoljalal Marjani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aman Mohammad Gharanjik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdoljalal Marjani.

Ethics declarations

Conflict of interest

The authors declared no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marjani, A., Gharanjik, A.M. Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan. Ind J Clin Biochem 33, 208–213 (2018). https://doi.org/10.1007/s12291-017-0660-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-017-0660-7

Keywords

Search

Navigation